Clinical Trial Update: PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating oral rosiglitazone with the Vision Stent to prevent restenosis in diabetics with coronary lesions; the status of the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Diabetes Mellitus

Drugs mentioned

• Avandia (rosiglitazone)
• Vision Stent

Snippet

Sponsor: Gold, Herman K., MD | Conditions: Coronary Artery Disease, Diabetes Mellitus | Phase 2, Phase 3 | Status: UNKNOWN